RT Journal Article
SR Electronic
T1 COVID-19 mRNA Booster Vaccines Elicit Strong Protection Against SARS-CoV-2 Omicron Variant in Patients with Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.28.21268398
DO 10.1101/2021.12.28.21268398
A1 Zeng, Cong
A1 Evans, John P.
A1 Chakravarthy, Karthik
A1 Qu, Panke
A1 Reisinger, Sarah
A1 Song, No Joon
A1 Rubinstein, Mark P.
A1 Shields, Peter G.
A1 Li, Zihai
A1 Liu, Shan-Lu
YR 2021
UL http://medrxiv.org/content/early/2021/12/30/2021.12.28.21268398.abstract
AB Following its emergence in late November of 2020, the SARS-CoV-2 Omicron (B.1.1.529) variant has caused major global public health concerns. We recently demonstrated that in healthy adults the Omicron variant exhibits strong resistance to immunity induced by two doses of the mRNA vaccines, but a booster mRNA vaccine dose can provide strong protection against Omicron. However, it is currently unknown how well these mRNA vaccine boosters protect immunocompromised groups, including cancer patients, from the Omicron variant. Here we show that (1) neutralizing antibody (nAb) titers against the Delta and Omicron variants in cancer patients after two-dose mRNA vaccines are 4.2-fold and 21.3-fold lower, respectively, compared to the ancestral D614G, and (2) nAb titers against the Delta and Omicron variants in boosted cancer patients are 3.6-fold and 5.1-fold lower, respectively, compared to D614G. Our findings highlight the effectiveness and need for booster vaccination strategies in immunocompromised groups including cancer patients to protect from the Omicron variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a fund provided by an anonymous private donor to The Ohio State University to S.-L.L. S.-L.L. was additionally supported in part by NIH R01 AI150473. Z.L. was supported by The Ohio State University Comprehensive Cancer Center Cancer Center Support Grant (P30CA016058), and multiple NIH grants (R01 DK105033; R01 AI077283; R01 CA213290; P01 CA186866; R01 CA255334; P30 CA016058). P.G.S. was supported by multiple NIH grants including NCI P30 CA016058. S.R. and Z.L. were supported by the Peletonia Institute for Immune-Oncology. The Pelotonia Institute for Immuno-Oncology (PIIO) is funded in part by the Pelotonia community and the Ohio State University Comprehensive Cancer Center (OSUCCC) (P30CA016058). The support from the OSUCCC Shared Resources includng Flow Cytometry and Clinical Treatment Unit and Clinical Trials Processing Laboratory is greatly appreciated.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was performed under an approved IRB protocol #2021C0041 by The Ohio State University Biomedical Sciences Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.